Drug intelligence / Profile preview

RG002-03

Development stage: Preclinical
Lead developer: RinuaGene Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RG002-03 is an investigational mRNA-based therapeutic vaccine developed by RinuaGene Biotechnology. It is designed to treat diseases caused by Human Papillomavirus (HPV), specifically Recurrent Respiratory Papillomatosis (RRP) and Condyloma Acuminatum (genital warts). The vaccine works by delivering mRNA encoding HPV-specific antigens into the patient's cells, which then produce these antigens to trigger a targeted immune response against HPV-infected tissues. As of early 2024, the program is in the IND-enabling phase of development.

Beyond the preview

Go deeper on RG002-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG002-03.

Explore the full profile